



**XTL Biopharmaceuticals to Present at the
Rodman & Renshaw 9th Annual Health Care Conference**

VALLEY COTTAGE, NEW YORK, October 29, 2007 – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Health Care Conference. Mr. Bentsur will present an overview of the Company including a discussion of Bicifadine, the Company's late-stage clinical compound for the treatment of neuropathic pain. Mr. Bentsur's presentation will take place on Monday, November 5, 2007 at 8:50 am EST at the New York Palace Hotel in New York City.

A live webcast of the presentation will be available at: <http://www.wsw.com/webcast/rrshq12/xtlb>. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225